A detailed history of Blueshift Asset Management, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Blueshift Asset Management, LLC holds 339 shares of REGN stock, worth $265,270. This represents 0.09% of its overall portfolio holdings.

Number of Shares
339
Holding current value
$265,270
% of portfolio
0.09%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1024.09 - $1201.76 $347,166 - $407,396
339 New
339 $356,000
Q2 2023

Aug 15, 2023

BUY
$700.03 - $830.35 $980,042 - $1.16 Million
1,400 New
1,400 $1.01 Million
Q4 2022

Feb 14, 2023

BUY
$705.89 - $766.39 $232,943 - $252,908
330 New
330 $238,000
Q1 2022

May 12, 2022

SELL
$595.12 - $698.43 $471,930 - $553,854
-793 Closed
0 $0
Q4 2021

Feb 11, 2022

SELL
$543.48 - $670.97 $428,805 - $529,395
-789 Reduced 49.87%
793 $501,000
Q3 2021

Nov 12, 2021

BUY
$574.03 - $680.96 $908,115 - $1.08 Million
1,582 New
1,582 $957,000
Q2 2021

Aug 13, 2021

SELL
$472.8 - $558.54 $1.08 Million - $1.27 Million
-2,282 Closed
0 $0
Q1 2021

May 06, 2021

BUY
$446.73 - $548.2 $1.02 Million - $1.25 Million
2,282 New
2,282 $1.08 Million
Q1 2020

May 14, 2020

SELL
$336.18 - $494.43 $3.7 Million - $5.45 Million
-11,019 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$274.13 - $376.51 $2.57 Million - $3.54 Million
9,389 Added 576.01%
11,019 $4.14 Million
Q3 2019

Nov 12, 2019

BUY
$273.46 - $318.39 $445,739 - $518,975
1,630 New
1,630 $452,000
Q2 2019

Aug 14, 2019

SELL
$299.6 - $414.82 $266,644 - $369,189
-890 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$372.08 - $439.57 $331,151 - $391,217
890 New
890 $365,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $83.9B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Blueshift Asset Management, LLC Portfolio

Follow Blueshift Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blueshift Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Blueshift Asset Management, LLC with notifications on news.